AnaptysBio, Inc.（ANAB）资讯与事件ANABAnaptysBio, Inc.

AnaptysBio Announces GSK Receives FDA Approval for Jemperli

AnaptysBio (ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK (GSK) company, and Quimilza with Vanda, announced that GSK has received U.S. Food and Drug Administration approval for Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high/ mismatch repair deficient locally advanced rectal cancer. GSK plans to present full data from the AZUR-1 interim analysis as a late-breaking abstract at ESMO Congress 2026 in Madrid, Spain on October 25, AnaptysBio noted.

Nasdaq Hits Record High Driven by AI Stocks Surge

The major averages started the week sharply higher, with the rise in AI-related stocks driving the tech-dominant Nasdaq Composite to record high on a 2.3% surge.   Within the benchmark S&P 500, Communication Services sector was the best-performing sector, paced by outsized 11% gains at Metato its best levels of the year amid strong adoption of its Muse AI agent.   Semiconductors was also one of the best-performing industries within the Technology sector, while Airlines were lifted by another steep decline in oil prices.  Energy was predictably the worst-performing sector benchmark, as WTI Crude Oil continued to retreat to $92 per barrel.In the opening hour of the evening session, index futures are anticipating more strength in tech, with Nasdaq 100 contract up 0.2%.  S&P e-minis are flat.  AutoZoneis the lone S&P 500 component reporting earnings on Tuesday.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -AnaptysBioup 4.7%ALSO HIGHER -Vicorup 12.5% after above-consensus pre-announcementBanco Bradesco S.A.up 2.8% after insider buyGameStop Corp.up 2.8% after insider buyRush Street Interactiveup 1.3% after being started with a Buy at StifelLOWER -Valero Energydown 0.6% after Jefferies downgradeMarathon Petroleumdown 0.5% after Jefferies downgrade

Jemperli Reports Q2 Revenue of $27.5M, Beating Consensus

Reports Q2 revenue $27.5M, consensus $20.12M. Cash, cash equivalents and investments totaled $164.1M as of June 30, compared to $211.6M as of December 31, 2025, for a decrease of $47.5M due primarily to $72.9M for operating activities offset by $25.4M received from stock option exercises. "Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro," said Daniel Faga, CEO. "In addition to Jemperli, we anticipate FDA approval of Quimilza in GPP in December 2026."